Shareholding for the Period Ended June 30, 2016
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here20-07-2016
Shareholding for the Period Ended June 30, 2016
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click hereDisclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
Sunanda Jain has submitted the disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Sunanda Jain has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
Sunanda Jain has submitted the disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011Panacea Biotec shares surge 10% on launch of diabetes drug
Panacea Biotec locked in upper circuit of 10 per cent on Tuesday after the company informed bourses that it has introduced indigenously developed high quality antidiabetic drugPanacea Biotec Launches - TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)
Panacea Biotec Ltd has informed BSE regarding a Press Release dated June 28, 2016 titled "Panacea Biotec Launches - TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)".Standalone & Consolidated Financial Results, Auditors Report for March 31, 2016
Panacea Biotec Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Consolidated Financial Results for the period ended March 31, 20163. Standalone Auditors Report for the period ended March 31, 20164. Consolidated Auditors Report for the period ended March 31, 2016Board Intimation for Results & Closure of Trading Window
Panacea Biotec Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 27, 2016, inter alia, to consider and approve the Audited Financial Results for the Quarter / Financial Year ended March 31, 2016. Further, in view of inadequate profits / losses, the Board may not be able to recommend any dividend in the Board Meeting....Shareholding for the Period Ended March 31, 2016
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here